Eyveris is the first commercial technology focused on tear film–formulation interactions. Developed through years of ocular-interface research and industrial formulation collaborations, it combines dynamic in vitro experiments with molecular in silico analysis to rank formulations, explain mechanisms and guide preclinical development decisions before committing candidates to more costly downstream studies.
Immediately after instillation, carriers, excipients, preservatives and APIs reorganise at the tear film. This early event can influence stability, tolerability and delivery, yet it is rarely measured as a dedicated development endpoint.
Cell and tissue assays remain essential, but they observe biological consequences after the formulation has already interacted with the ocular interface. Eyveris adds the missing preclinical layer upstream.
A formulation can perform differently because of carrier architecture, excipient localisation, API partitioning or lipid-layer disruption. Our integrated technology does not only show what happened; it helps explain why.
One formulation question, approached through complementary in vitro and molecular in silico readouts and translated into a practical preclinical decision.
Quantify tear-film integrity, break-up, inhomogeneity and formulation-dependent behaviour under controlled instillation and blink-like conditions.
Study carrier structure, excipient–lipid interactions, API distribution and molecular reorganisation at the tear-film interface.
Receive a formulation ranking, root-cause interpretation, optimisation hypotheses and recommendations for the next development step.
Eyveris is built on peer-reviewed research by our founders and collaborators, together with formulation-development projects performed with pharmaceutical industry partners. Three representative studies established the scientific basis of the technology across formulation comparison, preservative interactions and drug–lipid behaviour. The platform has since been developed substantially further for commercial preclinical use.
Eyveris works as a scientific formulation partner rather than a generic testing vendor. A focused preclinical study can answer a defined question quickly, then expand only where the evidence justifies it. Our technology has been refined through collaborations on commercial ophthalmic formulations, and every new project further expands this knowledge base.
Following an initial scientific discussion, we define the formulation question, required materials, study scope, confidentiality framework and decision criteria before issuing a project proposal.
Define the formulation question, comparator strategy and decision the study should support. No confidential composition is required for the first conversation.
Typically 2–4 formulations plus a comparator, combining selected in vitro and molecular in silico readouts. Turnaround is typically a few weeks, depending on scope and material availability.
Discuss the ranking, mechanism, remaining uncertainty and the most informative formulation or downstream-development action.
Clear maturity positioning matters in pharmaceutical collaboration. We separate current commercial capability from technologies under active development.
Available for focused formulation comparisons, mechanistic studies and preclinical development support.
An acellular glycocalyx-relevant platform being developed to extend the Eyveris decision layer from tear film to the corneal surface.
Four scientist-founders with experience spanning academic research, industrial formulation collaborations and technology translation.
Tear-film biophysics, molecular in silico modelling and translational ocular-interface science.
Surface and interface chemistry, lipid systems and formulation-relevant interactions.
Experimental platform development, quantitative analysis and reproducible workflows.
Pharmaceutical partnerships, customer development and strategic collaboration design.
We will tell you directly whether tear-film in vitro testing and molecular in silico analysis can add useful evidence to your preclinical program—and what a focused study would look like. Whether you are comparing commercial formulations or developing a new one, we are happy to discuss where tear-film science can reduce uncertainty.
Initial scientific discussions are typically led by Prof. Lukasz Cwiklik, Eyveris CEO and co-founder.